Immunocore Holdings PLC Sponsored ADR (IMCR) reported $97.96 million in revenue for the quarter ended June 2025, representing a year-over-year increase of 29.9%. EPS of -$0.20 for the same period compares to -$0.23 a year ago.
The reported revenue represents a surprise of +5.74% over the Zacks Consensus Estimate of $92.64 million. With the consensus EPS estimate being -$0.21, the EPS surprise was +4.76%.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Immunocore performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Geographic Revenue- United States: $64.09 million versus $59.44 million estimated by two analysts on average.
- Geographic Revenue- International: $0.84 million versus the two-analyst average estimate of $4.92 million.
- Geographic Revenue- Europe: $33.04 million versus $28.27 million estimated by two analysts on average.
View all Key Company Metrics for Immunocore here>>>
Shares of Immunocore have returned -7.2% over the past month versus the Zacks S&P 500 composite's +1.2% change. The stock currently has a Zacks Rank #1 (Strong Buy), indicating that it could outperform the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Immunocore Holdings PLC Sponsored ADR (IMCR): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
